Illumina · Q3 2021 earnings

Briefing

Illumina's financial results exceeded expectations, driven by clinical market expansion and record shipments for both clinical and research purposes.

Illumina reported strong financial results for the third quarter of fiscal year 2021, with revenue of $1,108 million, a 40% increase compared to the prior year period. GAAP net income was $317 million, or $2.08 per diluted share, and non-GAAP net income was $221 million, or $1.45 per diluted share.

• Revenue of $1,108 million, a 40% increase compared to the prior year period
• GAAP net income for the quarter of $317 million, or $2.08 per diluted share, which included a $900 million gain from our previously held investment in GRAIL and $654 million in day one compensation expense related to the GRAIL acquisition.
• Non-GAAP net income for the quarter of $221 million, or $1.45 per diluted share, which included dilution from GRAIL non-GAAP operating loss of $0.19 per diluted share and incremental dilution from the 9.8 million shares issued to fund the GRAIL acquisition of $0.06 per diluted share.
• The company held $1.3 billion in cash, cash equivalents and short-term investments.

Headline financials

Revenue & EPS history

For fiscal 2021, the company now expects both consolidated and Core Illumina revenue growth of approximately 36%. The company now expects GAAP earnings per diluted share of $4.41 to $4.51, and non-GAAP earnings per diluted share of $5.50 to $5.60, which includes dilution from GRAIL non-GAAP operating loss of approximately $1.00 and incremental dilution from the 9.8 million shares issued to fund the GRAIL acquisition of $0.15.